1型糖尿病青少年微血管并发症30年趋势
该研究评估了1990至2019年间2761名12-20岁1型糖尿病青少年的微血管并发症趋势,共5487次访视。视网膜病变和早期白蛋白排泄率升高先降后稳,周围神经异常率下降,而心率变异性异常和白蛋白尿无变化;HbA1c达标率随时间下降。
要点
- 视网膜病变和早期白蛋白尿比例先降后稳,周围神经异常率下降。
- HbA1c<7.0%达标率随时间下降,而MDI/CSII使用增加。
- HbA1c变异度与早期白蛋白尿、白蛋白尿和HRV异常相关。
核心结论
- 糖尿病并发症随时间下降后趋于稳定。
- 研究支持更低的血糖目标、CSII使用及针对可改变风险因素和HbA1c变异度以降低并发症风险。
研究设计与样本
- 研究纳入2761名12-20岁、病程≥5年的1型糖尿病青少年,共5487次访视,评估1990-1999、2000-2009和2010-2019三个十年间的并发症趋势。
- 采用广义估计方程分析十年间与可改变风险因素的关联,并用变异系数评估HbA1c变异度。
主要发现
- 视网膜病变比例从T1的40%降至T2的21%和T3的20%(P<0.001)。
- 平均白蛋白/肌酐比早期升高比例从T1的35%降至T2的29%和T3的28%(P=0.009)。
- 周围神经异常率从T2的35%降至T3的28%(P=0.007)。
- 心率变异性异常率T2为37%、T3为38%(P=0.884),白蛋白尿比例T1为6%、T2为4%、T3为4%(P=0.164),均无显著变化。
- HbA1c<7.0%达标比例从T1的7.4%降至T2的9.6%和T3的14.1%。
关键数值与推荐
- 在多变量模型中,每日两次胰岛素注射相比MDI/CSII与视网膜病变(OR 1.59 [95%CI 1.23-2.06; P<0.001])和早期白蛋白排泄率升高(OR 1.26 [95%CI 1.06-1.48]; P=0.007)相关。
- 调整平均HbA1c后,较高的HbA1c变异度与早期白蛋白排泄率/肌酐比升高(OR 1.27 [95%CI 1.05-1.53; P=0.015])、白蛋白尿(OR 1.26 [95%CI 1.04-1.52; P=0.018])和HRV异常(OR 1.49 [95%CI 1.08-2.05; P=0.015])相关。
临床怎么用
- 对1型糖尿病青少年应考虑更低的血糖目标。
- 优先使用CSII或MDI而非每日两次胰岛素注射。
- 关注并干预可改变风险因素及HbA1c变异度以降低并发症风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine trends in microvascular complications in adolescents from 1990 to 2019. RESEARCH DESIGNS AND METHODS: Retinopathy, albuminuria, and peripheral and autonomic nerve function (pupil size and heart rate variability [HRV]) were assessed in 2,761 adolescents aged 12-20 years (duration ≥5 years) over 5,487 visits. Generalized estimating equations were used to examine the association between decades T1 (1990-1999), T2 (2000-2009), and T3 (2010-2019), and modifiable risk factors, including HbA1c variability, were assessed by coefficient of variation (CV). RESULTS: Retinopathy (T1 40%, T2 21%, T3 20%; P < 0.001) and early elevation of mean albumin-to-creatinine ratio (ACR) (T1 35%, T2 29%, T3 28%; P = 0.009) plateaued and peripheral nerve abnormality rates decreased (T2 35%, T3 28%; P = 0.007), while HRV abnormality (T2 37%, T3 38%; P = 0.884) and albuminuria (T1 6%, T2 4%, T3 4%; P = 0.164) were unchanged. Over time, multiple daily injection (MDI)/continuous subcutaneous insulin infusion (CSII) use increased, with a decrease in the proportion of adolescents achieving HbA1c <7.0% (T1 7.4%, T2 9.6%, T3 14.1%). In a multivariable model including HbA1c, HbA1c CV, diabetes duration, diastolic blood pressure, and insulin dose per kilogram body weight, retinopathy and early elevation of albumin excretion rate (AER) were associated with twice-daily insulin versus MDI/CSII (odds ratio 1.59 [95% CI 1.23-2.06; P < 0.001], 1.26 [1.06-1.48]; P = 0.007]). After adjusting for mean intrapersonal HbA1c, higher HbA1c CV was associated with early elevation of AER/ACR (1.27 [1.05-1.53; P = 0.015]), albuminuria (1.26 [1.04-1.52; P = 0.018]), and HRV abnormality (1.49 [1.08-2.05; P = 0.015]). CONCLUSIONS: Diabetes complications decreased then plateaued over time. These findings support lower glycemic targets, CSII use, and targeting of modifiable risk factors and HbA1c CV to reduce complications risk in youth with type 1 diabetes. The role of hybrid closed-loop therapy should be evaluated in the future.
引用
- Calligaro LI, Liew G, Cho YH, et al. 30-Year Trends in Microvascular Complications and Treatment in Adolescents With Type 1 Diabetes. Diabetes Care. 2026. PMID: 42418171. doi:10.2337/dc26-0388
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。